We evaluate the therapeutic potential of safe compounds to develop proprietary combination drugs that delay the onset of age-related diseases by influencing the aging process
Biology of Aging
At Rejuvenate Biomed, we research the biology of aging and identify opportunities to impact the aging process. We develop medicines that can positively influence molecular mechanisms that lead to age-related and degenerative diseases, also known as the hallmarks of aging.
López-Otín et al., Hallmarks of aging, Cell (2023)
R² Platform
Our AI-enabled drug discovery platform combines an in silico selection process and a drug screening in the model organism C. elegans. By employing this unique integrated platform, we identify compounds with proven human safety that are predicted to synergistically impact longevity pathways.
Lead RJx-01
Our lead drug candidate RJx-01 is a safe combination drug for which we generated positive preclinical data that are supportive to prevent and/or treat multiple age-related diseases. A Phase 1b clinical trial is currently ongoing to evaluate its effect on sarcopenia, the progressive age-associated loss of muscle function and mass.